GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » EV-to-EBITDA

CSL (CSLLY) EV-to-EBITDA : 22.11 (As of May. 02, 2024)


View and export this data going back to 2008. Start your Free Trial

What is CSL EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CSL's enterprise value is $96,966 Mil. CSL's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $4,386 Mil. Therefore, CSL's EV-to-EBITDA for today is 22.11.

The historical rank and industry rank for CSL's EV-to-EBITDA or its related term are showing as below:

CSLLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.39   Med: 26.1   Max: 38.04
Current: 22.11

During the past 13 years, the highest EV-to-EBITDA of CSL was 38.04. The lowest was 16.39. And the median was 26.10.

CSLLY's EV-to-EBITDA is ranked worse than
72.75% of 466 companies
in the Biotechnology industry
Industry Median: 9.35 vs CSLLY: 22.11

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), CSL's stock price is $91.05. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.545. Therefore, CSL's PE Ratio for today is 35.78.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CSL EV-to-EBITDA Historical Data

The historical data trend for CSL's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL EV-to-EBITDA Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.77 30.14 28.44 26.06 26.27

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 26.06 - 26.27 -

Competitive Comparison of CSL's EV-to-EBITDA

For the Biotechnology subindustry, CSL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CSL's EV-to-EBITDA falls into.



CSL EV-to-EBITDA Calculation

CSL's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=96966.348/4385.5
=22.11

CSL's current Enterprise Value is $96,966 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $4,386 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL  (OTCPK:CSLLY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CSL's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=91.05/2.545
=35.78

CSL's share price for today is $91.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.545.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CSL EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CSL's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (CSLLY) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.